← back to search

Özgür Şahin

Medical University of South Carolina · US
Area of research
Cancer Research · Oncology
Research interest
Research interests include MicroRNA in disease regulation, Cancer Immunotherapy and Biomarkers, Cancer-related molecular mechanisms research, and RNA modifications and cancer.
h-index
40
citations
8,612
works
305
NIH funding
primary concept
email

Recent publications

Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer
Cancer Research 2024cited by 26position: lastdoi
Polyol pathway-generated fructose is indispensable for growth and survival of non-small cell lung cancer
Cell Death and Differentiation 2024cited by 19position: middledoi
Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer
bioRxiv (Cold Spring Harbor Laboratory) 2023cited by 2position: lastdoi
Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits
BMC Cancer 2021cited by 16position: middledoi
Coordinated regulation of WNT/β-catenin, c-Met, and Integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits
bioRxiv (Cold Spring Harbor Laboratory) 2021cited by 2position: middledoi
Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers
Cell Death and Differentiation 2019cited by 53position: middledoi
Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells
Cancer Research 2018cited by 128position: middledoi
Oncogenic Kinase–Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem–like Cells
Cancer Research 2018cited by 102position: middledoi
Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer
Oncogene 2018cited by 80position: lastdoi
14-3-3ζ Turns TGF-β’s Function from Tumor Suppressor to Metastasis Promoter in Breast Cancer by Contextual Changes of Smad Partners from p53 to Gli2
Cancer Cell 2015cited by 182position: middledoi
Abstract 241: A novel tumor suppressor miRNA co-regulating EMT and p53-independent cell survival in breast cancer
Cancer Research 2015cited by 0position: lastdoi
<scp>MicroRNA</scp>‐519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour‐suppressor genes in <scp>ER</scp>+ breast cancer
The Journal of Pathology 2014cited by 122position: middledoi
Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors reveals hypomethylation of <i>SPP1</i> as an independent prognostic factor
International Journal of Cancer 2014cited by 23position: lastdoi
Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models
Breast Cancer Research 2013cited by 72position: middledoi
A Network-Based Method to Assess the Statistical Significance of Mild Co-Regulation Effects
PLoS ONE 2013cited by 20position: middledoi
Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
Oncogene 2012cited by 286position: lastdoi
Global microRNA level regulation of EGFR‐driven cell‐cycle protein network in breast cancer
Molecular Systems Biology 2012cited by 201position: lastdoi
Diagnostic values of GHSR DNA methylation pattern in breast cancer
Breast Cancer Research and Treatment 2012cited by 20position: middledoi
Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα‐positive breast cancer
International Journal of Cancer 2012cited by 10position: middledoi
Abstract A14: Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
Clinical Cancer Research 2012cited by 3position: lastdoi
Abstract 5005: Large-scale DNA methylation profiling in gastrointestinal stromal tumors (GIST) reveals epigenetic regulation of SPP1 as an independent prognostic factor
Cancer Research 2012cited by 0position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Stefan Wiemann · German Cancer Research Center13 papers (2012–2024)Jitao David Zhang · Roche (Switzerland)6 papers (2012–2015)Aoife Ward · German Cancer Research Center6 papers (2012–2014)Özge Saatci · University of South Carolina5 papers (2018–2024)Stefan Uhlmann · German Cancer Research Center5 papers (2012–2021)Aleksandra Balwierz · Princess Máxima Center5 papers (2012–2014)Yasser Riazalhosseini · National Institute of Pathology4 papers (2012–2014)Jörg D. Hoheisel · German Cancer Research Center3 papers (2012–2014)Heiko Mannsperger · Software (Germany)3 papers (2012–2021)Paolo Ceppi · Friedrich-Alexander-Universität Erlangen-Nürnberg3 papers (2018–2024)Aarif Siddiqui · Friedrich-Alexander-Universität Erlangen-Nürnberg3 papers (2018–2024)Ulrike Korf · German Cancer Research Center3 papers (2012–2021)Özge Akbulut · University of South Carolina3 papers (2018–2024)Annemarie Schwab · Friedrich-Alexander-Universität Erlangen-Nürnberg3 papers (2018–2024)Umar Raza · Shenzhen University3 papers (2015–2018)Tim Beißbarth · Universitätsmedizin Göttingen2 papers (2021–2021)Janine Jung · German Cancer Research Center2 papers (2021–2021) · 2 papers (2012–2013)Abbas Agaimy · Harvard University2 papers (2012–2014) · 2 papers (2021–2021)